NPCE logo

NPCE
NeuroPace Inc

330
Mkt Cap
$561.54M
Volume
133,555.00
52W High
$18.98
52W Low
$7.56
PE Ratio
-25.55
NPCE Fundamentals
Price
$16.86
Prev Close
$16.54
Open
$16.73
50D MA
$14.68
Beta
1.17
Avg. Volume
260,671.35
EPS (Annual)
-$0.656
P/B
29.74
Rev/Employee
$478,401.91
$515.01
Loading...
Loading...
News
all
press releases
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence...
Business Wire·4d ago
News Placeholder
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the company, MarketBeat...
MarketBeat·5d ago
News Placeholder
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual...
Business Wire·21d ago
News Placeholder
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·29d ago
News Placeholder
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
NPCE rides strong RNS adoption and AI innovation, but near-term profitability faces pressure as IGE expansion and revenue contribution remain uncertain.
Zacks·29d ago
News Placeholder
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·29d ago
News Placeholder
NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company
Wells Fargo & Company upgraded shares of NeuroPace to a "strong-buy" rating in a research report on Wednesday...
MarketBeat·1mo ago
News Placeholder
NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut NeuroPace from a "buy" rating to a "hold" rating in a research note on Sunday...
MarketBeat·2mo ago
News Placeholder
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.
Zacks·2mo ago
<
1
2
...
>

Latest NPCE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.